Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment

New England Journal of Medicine

Volumn 377, Issue 15, 2017, Pages 1448-1455

  Gane, Edward ^a   Lawitz, Eric ^b   Pugatch, David ^c   Papatheodoridis, Georgios ^d   Bräu, Norbert ^e,f   Brown, Ashley ^g   Pol, Stanislas ^h   Leroy, Vincent ⁱ   Persico, Marcello ^j   Moreno, Christophe ^m   Colombo, Massimo ^k,l   Yoshida, Eric M ⁿ   Nelson, David R ^o   Collins, Christine ^c   Lei, Yang ^c   Kosloski, Matthew ^c   Mensa, Federico J ^c  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c ABBVIE INC   (United States)

^d UNIVERSITY OF ATHENS   (Greece)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^h Groupe Hospitalier Cochin Saint Vincent de Paul   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY OF SALERNO   (Italy)

^k HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^l UNIVERSITY OF MILAN   (Italy)

^m ERASME HOSPITAL   (Belgium)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLECAPREVIR; INTERFERON; PEGINTERFERON; PIBRENTASVIR; RIBAVIRIN; SOFOSBUVIR; ABT-493; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG COMBINATION; QUINOXALINE DERIVATIVE; SULFONAMIDE; VIRUS RNA;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RENAL REPLACEMENT THERAPY; SEVERE RENAL IMPAIRMENT; SUSTAINED VIROLOGIC RESPONSE; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; VERY ELDERLY; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG COMBINATIONS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; QUINOXALINES; RENAL INSUFFICIENCY, CHRONIC; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD;

EID: 85031034435     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1704053     Document Type: Article

References (30)

1. Bergman S, Accortt N, Turner A, Glaze J. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis 2005;45:684-9.
2. Niu MT, Coleman PJ, Alter MJ. Multi-center study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. Am J Kidney Dis 1993;22:568-73.
3. Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holland PV. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 1990; 112:958-60.
4. Lee JJ, Lin MY, Chang JS, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One 2014; 9(6):e100790.
5. Okoh EJ, Bucci JR, Simon JF, Harrison SA. HCV in patients with end-stage renal disease. Am J Gastroenterol 2008;103:2123-34.
6. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
7. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38.
8. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385:1124-35.
9. Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extra-hepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 2016;3:3-14.
10. Gupta SK, Pittenger AL, Swan SK, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002;42:1109-15.
11. Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol 2015;12:284-92.
12. Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol 2015;11:172-82.
13. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77.
14. Ouwerkerk-Mahadevan S, Beumont-Mauviel M, Mortier S, et al. Evaluation of the pharmacokinetics and renal excretion of simeprevir in subjects with renal impairment. Drugs R D 2015;15:261-70.
15. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
16. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-42.
17. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-54.
18. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017; 66:153-94.
19. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-45.
20. Gane E, Lamoglia RS, Cohen E, et al. RUBY-II: efficacy and safety of a ribavirin-free ombitasvir/paritaprevir/ritonavir ± dasabuvir regimen in patients with severe renal impairment or end-stage renal disease and HCV genotypes 1a or 4 infection. Presented at The Liver Meeting 2016, Boston, November 11–15, 2016.
21. Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 2016;150:1590-8.
22. Ng TRT, Middleton T, McDaniel K, et al. ABT-493, a potent HCV NS3/4A protease inhibitor with broad genotypic coverage. Presented at the 21st Annual Conference on Retroviruses and Opportunistic Infections, Boston, March 3–6, 2014. abstract.
23. Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Anti-microb Agents Chemother 2017;61(5): e02558-16.
24. Kosloski MP. Pharmacokinetics, safety, and tolerability of next generation direct-acting antivirals ABT-493 and ABT-530 in subjects with hepatic impairment. Presented at the International Liver Conference 2016, Barcelona, April 13–17, 2016. abstract.
25. Kosloski MP. Hemodialysis does not affect the pharmacokinetics of ABT-493 or ABT-530. Presented at The Liver Meeting 2016, Boston, November 11–15, 2016. abstract.
26. Cacoub P, Desbois AC, Isnard-Bagnis C, Rocatello D, Ferri C. Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol 2016;65:Suppl: S82-S94.
27. Hassanein T, Vierling J, Reddy KR, et al. RUBY-I, Cohort 2: treatment of HCV genotype 1 infection in patients with severe or end-stage renal disease, including patients with cirrhosis. Presented at the Asian Pacific Association for the Study of the Liver Single Topic Conference on Hepatitis C, Kaohsiung, Taiwan, June 10–12, 2016. abstract.
28. Anavekar NS, McMurray JJV, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-95.
29. Gilead Sciences. Sovaldi prescribing information. 2017 (https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/ sovaldi/sovaldi_pi.pdf).
30. Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 2016;36:807-16.